ArticleFrontiers in oncology2026
TyG index is associated with colorectal adenomatous polyps and genetically linked to colon polyps: a cross-sectional and Mendelian randomization study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The triglyceride-glucose (TyG) index, a simple and validated surrogate marker of insulin resistance, may be clinically relevant to colorectal polyp development because insulin resistance can promote colorectal neoplasia through hyperinsulinemia, chronic inflammation, oxidative stress, and dysregulated insulin-like growth factor signaling. However, the relationship between TyG index and colorectal polyps remains incompletely understood. This study aimed to investigate the association between TyG index and colorectal polyp risk using both observational and genetic approaches. Methods: We conducted a cross-sectional study of 4,263 patients undergoing colonoscopy. Associations between TyG index and colorectal adenomatous polyps were assessed using multivariable logistic regression. A two-sample Mendelian randomization (MR) analysis evaluated potential causal effects, with inverse-variance weighted (IVW) method as primary analysis and multiple sensitivity analyses. Results: Although the crude distribution of colorectal polyps across TyG quartiles did not show a strictly monotonic pattern, participants in different TyG quartiles differed substantially in age, sex distribution, BMI, lifestyle factors, comorbidities, and metabolic profiles. Therefore, multivariable logistic regression was performed to account for potential confounding. Higher TyG index was significantly associated with increased prevalence of colorectal adenomatous polyps after full adjustment (odds ratio [OR] 1.13, 95% CI: 1.01-1.27; P-trend = 0.032). Restricted cubic spline analysis showed no evidence of a nonlinear association between the TyG index and colorectal adenomatous polyp risk (P for nonlinearity = 0.459), supporting the use of a linear model in this dataset. MR analysis supported a observational and potential causal association between genetically predicted TyG index and colon polyps (inverse-variance weighted OR: 1.20, 95% CI: 1.10-1.31; P < 0.001), with consistent results across sensitivity analyses and no evidence of directional pleiotropy (P = 0.884). However, no significant association was found for rectal polyps. Conclusion: Both observational evidence and genetic evidence support a positive association between the TyG index and colon polyps, whereas the MR analysis did not provide evidence for a causal association with rectal polyps. These findings suggest the potential utility of the TyG index in risk stratification and underscore the role of insulin resistance in the pathogenesis of colorectal neoplasia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.